Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Aclaris Therapts (ACRS)

Aclaris Therapts (ACRS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 51,495
  • Shares Outstanding, K 41,866
  • Annual Sales, $ 4,230 K
  • Annual Income, $ -161,350 K
  • 60-Month Beta 1.13
  • Price/Sales 12.28
  • Price/Cash Flow N/A
  • Price/Book 0.88
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.10
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 05/13/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.34
  • Number of Estimates 3
  • High Estimate -0.34
  • Low Estimate -0.35
  • Prior Year -0.72
  • Growth Rate Est. (year over year) +52.78%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0200 +20.59%
on 04/23/20
1.5000 -18.00%
on 05/12/20
+0.1300 (+11.82%)
since 04/22/20
3-Month
0.7000 +75.71%
on 03/19/20
1.5000 -18.00%
on 05/12/20
-0.2200 (-15.17%)
since 02/21/20
52-Week
0.7000 +75.71%
on 03/19/20
5.3700 -77.09%
on 06/20/19
-3.8400 (-75.74%)
since 05/22/19

Most Recent Stories

More News
Will Aclaris Therapeutics Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor Aclaris Therapeutics

ACRS : 1.2300 (-0.81%)
All You Need to Know About Aclaris (ACRS) Rating Upgrade to Buy

Aclaris (ACRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

ACRS : 1.2300 (-0.81%)
Aclaris: 1Q Earnings Snapshot

WAYNE, Pa. (AP) _ Aclaris Therapeutics Inc. (ACRS) on Thursday reported a loss of $15.6 million in its first quarter.

ACRS : 1.2300 (-0.81%)
Aclaris Therapeutics Reports First Quarter 2020 Financial Results and Provides R&D and Business Highlights

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced its financial results for the first quarter of 2020 and provided...

ACRS : 1.2300 (-0.81%)
Aclaris Therapeutics (ACRS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Aclaris (ACRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ACRS : 1.2300 (-0.81%)
Aclaris (ACRS) Upgraded to Buy: Here's Why

Aclaris (ACRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

ACRS : 1.2300 (-0.81%)
Aclaris Therapeutics Secures $11 Million Term Loan Facility

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company, today announced that it has entered into a loan and security agreement with Silicon Valley Bank ("SVB") pursuant to...

ACRS : 1.2300 (-0.81%)
Aclaris: 4Q Earnings Snapshot

WAYNE, Pa. (AP) _ Aclaris Therapeutics Inc. (ACRS) on Tuesday reported a loss of $18.6 million in its fourth quarter.

ACRS : 1.2300 (-0.81%)
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides R&D and Business Highlights

-- Positive Preliminary Results from Phase 1 Single and Multiple Ascending Dose Trial of ATI-450, an Investigational Oral MK2 Inhibitor

ACRS : 1.2300 (-0.81%)
Aclaris Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results on February 25, 2020

Aclaris Therapeutics, Inc. (NASDAQ: ACRS) a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced it will report financial results for the fourth quarter and...

ACRS : 1.2300 (-0.81%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade ACRS with:

Business Summary

Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription...

See More

Key Turning Points

2nd Resistance Point 1.3167
1st Resistance Point 1.2733
Last Price 1.2300
1st Support Level 1.1933
2nd Support Level 1.1567

See More

52-Week High 5.3700
Fibonacci 61.8% 3.5861
Fibonacci 50% 3.0350
Fibonacci 38.2% 2.4839
Last Price 1.2300
52-Week Low 0.7000

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar